Efficacy of Atropine Eye Drops for Suppressing Myopia Progression in Thai Children
Abstract
Objective: This retrospective cohort study aimed to assess the efficacy and safety of low-dose atropine eye drops in retarding myopic progression among school-age children at Siriraj hospital.
Materials and Methods: The medical records of 248 myopia-diagnosed patients were reviewed. All patients were received low-dose atropine eye drops and had at least one follow-up visit within 1 year after the treatment initiation. Spherical equivalent (SE) measurements were collected at pre- and post-treatment visits, as well as any reported side effects. Comparing the SE changes observed between the pre- and post-treatment periods, as well as between the two different concentrations of atropine was analyzed.
Results: A total of 495 eyes were analyzed, with 461 eyes receiving 0.01% atropine eye drops and 32 eyes being administered 0.05%. The demographic data between two groups showed no significant difference. The comparison of SE change one year prior to and one year after treatment in the 0.01% and 0.05% group yielded a p-value of less than 0.001 and 0.003, respectively, (SE change are -0.38 (-0.75-0.00) and -0.25 (-0.72-(-0.25)) in the 0.01% and 0.05% group, respectively). However, the between-group comparison of SE change at 6 months and 1 year showed no significant difference. Regarding side effects, one-third of the eyes in the 0.05% group (37.5%) experienced adverse effects while only eight eyes (1.7%) in the 0.01% group reported side effects.
Conclusion: This research contributes…
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.